Nutex Health heads into its third-quarter report with a peculiar setup: Wall Street expects earnings to fall sharply from the prior quarter, and that may be perfectly fine. The real question is not whether the company can repeat the blowout margins it posted last time. It is whether the cheaper arbitration cost structure management described is durable once the retroactive benefits that flattered the second quarter fall away.

Consensus calls for earnings of $5.53 per share on revenue of $216.9 million, figures that represent declines of roughly 29% and 19% from a year ago. Those comparisons look ugly, but the year-ago quarter was inflated by the ramp in independent dispute resolution (IDR) payments and a collection-rate true-up that pushed revenue per visit well above what management now calls steady state, roughly $4,000 to $4,200. More telling is the sequential picture. Revenue expectations sit slightly above the $210.8 million reported last quarter, while the EPS estimate is far below the $9.58 the company delivered. In other words, analysts are betting on modest top-line stability and a meaningful step down in profitability, which makes sense given how much of last quarter's strength came from an unusual source.

That source was the amended HaloMD agreement, which shifted fees to a pay-on-collected basis retroactive to 2024 and, together with a federal rule slashing the IDR administrative fee from $115 to $15, cut contract-services costs by about $52 million in the second quarter. Gross margin leapt to 67% from 51.2% a year earlier. Because part of that savings reflected a catch-up, the cleaner test arrives now. Management guided to a 25% to 30% reduction in normalized contract-services costs going forward. If this quarter's cost line lands in that zone while gross margin holds well above last year's level, the structural story is validated. If costs creep back toward historical norms, the second quarter will look more like a one-off accounting windfall than a reset.

Volume is the other half of the thesis. Same-hospital visits accelerated to 6.3% growth last quarter from just 0.6% in the first quarter, and total visits rose nearly 10%. Sustaining something close to that pace would show the improvement was not a single-quarter blip and would give the flat revenue-per-visit assumption room to produce growth. Updates on the three hospital openings slated for the second half, in West Little Rock, San Antonio and Jacksonville, plus early traction in the new endoscopy line, will indicate whether the self-funded expansion pipeline is on schedule. A weaker spot to monitor is in-network contracting, where management conceded rates are improving only slowly, leaving the company heavily reliant on the arbitration process and exposed to the kind of backlog swings that produced a $55 million ineligible-claim true-up late last year.

The market has already embraced the improving narrative. Shares have climbed about 26% since the last report while the S&P 500 was flat, and the stock trades near $208, comfortably above its 200-day average around $150. It remains roughly 8% below its post-earnings high of $226, so this is not a breakout setup, but the rally does raise the bar. Sentiment, meanwhile, remains firmly bearish and essentially unchanged from last quarter, suggesting skeptics have not been converted even as the price ran.

That divergence frames the report. A lower earnings number is expected and largely explained. What will determine whether the bullish narrative holds is evidence that normalized contract-services costs have truly fallen by a quarter or more, that same-hospital volume keeps compounding, and that cash generation stays strong without help from retroactive adjustments.